Podcast appearances and mentions of Jonathan A Bernstein

Listen in as Jonathan A. Bernstein, MD, and Ryan Haumschild, PharmD, MS, MBA, CPEL, discuss how to manage the multidisciplinary care of patients with systemic mastocytosis (SM) from both the allergy/immunology and pharmacy perspective, including:Strategies to better identify patients presenting with features of SM to facilitate timely diagnosisCurrent guideline-recommended treatment approachesEmerging data on new targeted agents for SMPharmacist-led strategies to help patients achieve better outcomes (e.g., specialist referral, polypharmacy counseling, and anaphylaxis education)PresentersJonathan A. Bernstein, MDProfessor of MedicineDivision of Rheumatology, Allergy and ImmunologyDepartment of Internal MedicineUniversity of Cincinnati College of MedicinePartner Advanced Allergy Services, LLCPartner Bernstein Clinical Research Center, LLCCincinnati, OhioRyan Haumschild, PharmD, MS, MBA, CPELVice President of Pharmacy, AmbulatoryEmory HealthcareWinship Cancer InstituteAtlanta, GeorgiaFull link to program page:https://bit.ly/3HcA8z2

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/FTH865. CME credit will be available until May 5, 2025.Chasing the Itch: Exploring the BTK Inhibitor Frontier In Chronic UrticariaThe University of Florida College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.SupportThis activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/FTH865. CME credit will be available until May 5, 2025.Chasing the Itch: Exploring the BTK Inhibitor Frontier In Chronic UrticariaThe University of Florida College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.SupportThis activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/FTH865. CME credit will be available until May 5, 2025.Chasing the Itch: Exploring the BTK Inhibitor Frontier In Chronic UrticariaThe University of Florida College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.SupportThis activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/FTH865. CME credit will be available until May 5, 2025.Chasing the Itch: Exploring the BTK Inhibitor Frontier In Chronic UrticariaThe University of Florida College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.SupportThis activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/FTH865. CME credit will be available until May 5, 2025.Chasing the Itch: Exploring the BTK Inhibitor Frontier In Chronic UrticariaThe University of Florida College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.SupportThis activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/FTH865. CME credit will be available until May 5, 2025.Chasing the Itch: Exploring the BTK Inhibitor Frontier In Chronic UrticariaThe University of Florida College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.SupportThis activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/FTH865. CME credit will be available until May 5, 2025.Chasing the Itch: Exploring the BTK Inhibitor Frontier In Chronic UrticariaThe University of Florida College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.SupportThis activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/FTH865. CME credit will be available until May 5, 2025.Chasing the Itch: Exploring the BTK Inhibitor Frontier In Chronic UrticariaThe University of Florida College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.SupportThis activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/WQU865. CME credit will be available until May 6, 2025.BTK Inhibition Transforming the Landscape of Chronic Spontaneous Urticaria Treatment In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/WQU865. CME credit will be available until May 6, 2025.BTK Inhibition Transforming the Landscape of Chronic Spontaneous Urticaria Treatment In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/WQU865. CME credit will be available until May 6, 2025.BTK Inhibition Transforming the Landscape of Chronic Spontaneous Urticaria Treatment In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/WQU865. CME credit will be available until May 6, 2025.BTK Inhibition Transforming the Landscape of Chronic Spontaneous Urticaria Treatment In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/WQU865. CME credit will be available until May 6, 2025.BTK Inhibition Transforming the Landscape of Chronic Spontaneous Urticaria Treatment In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/WQU865. CME credit will be available until May 6, 2025.BTK Inhibition Transforming the Landscape of Chronic Spontaneous Urticaria Treatment In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/WQU865. CME credit will be available until May 6, 2025.BTK Inhibition Transforming the Landscape of Chronic Spontaneous Urticaria Treatment In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/WQU865. CME credit will be available until May 6, 2025.BTK Inhibition Transforming the Landscape of Chronic Spontaneous Urticaria Treatment In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.

Allergic rhinitis affects an estimated 15% of the US population and is associated with impaired quality of life. JAMA Deputy Editor Mary McGrae McDermott, MD, discusses current evidence regarding the diagnosis and treatment of allergic rhinitis with author Jonathan A. Bernstein, MD, College of Medicine, University of Cincinnati. Related Content: Allergic Rhinitis

Go online to PeerView.com/CJC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this animated activity, an expert in dermatology discusses new and novel therapies addressing unmet patient needs in the management of chronic spontaneous urticaria (CSU). Upon completion of this CE activity, participants will be able to: Recognize CSU as a heterogeneous, disabling, and persistent disease with multiple comorbidities and consequences, Conduct a thorough medical history to guide the selection of adequate and relevant tests for the diagnostic workup in CSU, Discuss how recent insights into the pathogenesis of CSU have led to the development of novel therapeutic targets, Evaluate recent clinical trial data related to novel treatment options for CSU, Treat CSU in accordance with current evidence and expert recommendations, identifying patients who would likely derive benefit from newer therapeutic options.

Go online to PeerView.com/CJC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this animated activity, an expert in dermatology discusses new and novel therapies addressing unmet patient needs in the management of chronic spontaneous urticaria (CSU). Upon completion of this CE activity, participants will be able to: Recognize CSU as a heterogeneous, disabling, and persistent disease with multiple comorbidities and consequences, Conduct a thorough medical history to guide the selection of adequate and relevant tests for the diagnostic workup in CSU, Discuss how recent insights into the pathogenesis of CSU have led to the development of novel therapeutic targets, Evaluate recent clinical trial data related to novel treatment options for CSU, Treat CSU in accordance with current evidence and expert recommendations, identifying patients who would likely derive benefit from newer therapeutic options.

Go online to PeerView.com/CJC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this animated activity, an expert in dermatology discusses new and novel therapies addressing unmet patient needs in the management of chronic spontaneous urticaria (CSU). Upon completion of this CE activity, participants will be able to: Recognize CSU as a heterogeneous, disabling, and persistent disease with multiple comorbidities and consequences, Conduct a thorough medical history to guide the selection of adequate and relevant tests for the diagnostic workup in CSU, Discuss how recent insights into the pathogenesis of CSU have led to the development of novel therapeutic targets, Evaluate recent clinical trial data related to novel treatment options for CSU, Treat CSU in accordance with current evidence and expert recommendations, identifying patients who would likely derive benefit from newer therapeutic options.

Go online to PeerView.com/CJC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this animated activity, an expert in dermatology discusses new and novel therapies addressing unmet patient needs in the management of chronic spontaneous urticaria (CSU). Upon completion of this CE activity, participants will be able to: Recognize CSU as a heterogeneous, disabling, and persistent disease with multiple comorbidities and consequences, Conduct a thorough medical history to guide the selection of adequate and relevant tests for the diagnostic workup in CSU, Discuss how recent insights into the pathogenesis of CSU have led to the development of novel therapeutic targets, Evaluate recent clinical trial data related to novel treatment options for CSU, Treat CSU in accordance with current evidence and expert recommendations, identifying patients who would likely derive benefit from newer therapeutic options.

Go online to PeerView.com/CJC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this animated activity, an expert in dermatology discusses new and novel therapies addressing unmet patient needs in the management of chronic spontaneous urticaria (CSU). Upon completion of this CE activity, participants will be able to: Recognize CSU as a heterogeneous, disabling, and persistent disease with multiple comorbidities and consequences, Conduct a thorough medical history to guide the selection of adequate and relevant tests for the diagnostic workup in CSU, Discuss how recent insights into the pathogenesis of CSU have led to the development of novel therapeutic targets, Evaluate recent clinical trial data related to novel treatment options for CSU, Treat CSU in accordance with current evidence and expert recommendations, identifying patients who would likely derive benefit from newer therapeutic options.

Go online to PeerView.com/CJC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this animated activity, an expert in dermatology discusses new and novel therapies addressing unmet patient needs in the management of chronic spontaneous urticaria (CSU). Upon completion of this CE activity, participants will be able to: Recognize CSU as a heterogeneous, disabling, and persistent disease with multiple comorbidities and consequences, Conduct a thorough medical history to guide the selection of adequate and relevant tests for the diagnostic workup in CSU, Discuss how recent insights into the pathogenesis of CSU have led to the development of novel therapeutic targets, Evaluate recent clinical trial data related to novel treatment options for CSU, Treat CSU in accordance with current evidence and expert recommendations, identifying patients who would likely derive benefit from newer therapeutic options.

Go online to PeerView.com/CJC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this animated activity, an expert in dermatology discusses new and novel therapies addressing unmet patient needs in the management of chronic spontaneous urticaria (CSU). Upon completion of this CE activity, participants will be able to: Recognize CSU as a heterogeneous, disabling, and persistent disease with multiple comorbidities and consequences, Conduct a thorough medical history to guide the selection of adequate and relevant tests for the diagnostic workup in CSU, Discuss how recent insights into the pathogenesis of CSU have led to the development of novel therapeutic targets, Evaluate recent clinical trial data related to novel treatment options for CSU, Treat CSU in accordance with current evidence and expert recommendations, identifying patients who would likely derive benefit from newer therapeutic options.

Go online to PeerView.com/CJC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this animated activity, an expert in dermatology discusses new and novel therapies addressing unmet patient needs in the management of chronic spontaneous urticaria (CSU). Upon completion of this CE activity, participants will be able to: Recognize CSU as a heterogeneous, disabling, and persistent disease with multiple comorbidities and consequences, Conduct a thorough medical history to guide the selection of adequate and relevant tests for the diagnostic workup in CSU, Discuss how recent insights into the pathogenesis of CSU have led to the development of novel therapeutic targets, Evaluate recent clinical trial data related to novel treatment options for CSU, Treat CSU in accordance with current evidence and expert recommendations, identifying patients who would likely derive benefit from newer therapeutic options.

Go online to PeerView.com/CJC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this animated activity, an expert in dermatology discusses new and novel therapies addressing unmet patient needs in the management of chronic spontaneous urticaria (CSU). Upon completion of this CE activity, participants will be able to: Recognize CSU as a heterogeneous, disabling, and persistent disease with multiple comorbidities and consequences, Conduct a thorough medical history to guide the selection of adequate and relevant tests for the diagnostic workup in CSU, Discuss how recent insights into the pathogenesis of CSU have led to the development of novel therapeutic targets, Evaluate recent clinical trial data related to novel treatment options for CSU, Treat CSU in accordance with current evidence and expert recommendations, identifying patients who would likely derive benefit from newer therapeutic options.

Go online to PeerView.com/DRD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in atopic diseases discusses the relationship between type 2 inflammation and atopic diseases, as well as therapeutic options and strategies to improve patient quality of life. Upon completion of this activity, participants will be able to: Describe the relationship between type 2 inflammation and atopic diseases including asthma, atopic dermatitis, chronic rhinosinusitis with nasal polyps (CRS/NP), and eosinophilic esophagitis (EoE), as well as its relevance to novel biologic therapies, Assess the severity of allergic and inflammatory diseases according to evidence-based guidelines and impact on patient quality of life, Employ the latest clinical evidence with regard to efficacy and safety of novel and emerging biologic therapies to tailor treatment for patients with allergic and inflammatory diseases, Implement patient education and communication tactics in collaboration with other members of the healthcare team to improve patient adherence to medication regimens, self-management, and quality of life.

Go online to PeerView.com/DRD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in atopic diseases discusses the relationship between type 2 inflammation and atopic diseases, as well as therapeutic options and strategies to improve patient quality of life. Upon completion of this activity, participants will be able to: Describe the relationship between type 2 inflammation and atopic diseases including asthma, atopic dermatitis, chronic rhinosinusitis with nasal polyps (CRS/NP), and eosinophilic esophagitis (EoE), as well as its relevance to novel biologic therapies, Assess the severity of allergic and inflammatory diseases according to evidence-based guidelines and impact on patient quality of life, Employ the latest clinical evidence with regard to efficacy and safety of novel and emerging biologic therapies to tailor treatment for patients with allergic and inflammatory diseases, Implement patient education and communication tactics in collaboration with other members of the healthcare team to improve patient adherence to medication regimens, self-management, and quality of life.

Go online to PeerView.com/DRD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in atopic diseases discusses the relationship between type 2 inflammation and atopic diseases, as well as therapeutic options and strategies to improve patient quality of life. Upon completion of this activity, participants will be able to: Describe the relationship between type 2 inflammation and atopic diseases including asthma, atopic dermatitis, chronic rhinosinusitis with nasal polyps (CRS/NP), and eosinophilic esophagitis (EoE), as well as its relevance to novel biologic therapies, Assess the severity of allergic and inflammatory diseases according to evidence-based guidelines and impact on patient quality of life, Employ the latest clinical evidence with regard to efficacy and safety of novel and emerging biologic therapies to tailor treatment for patients with allergic and inflammatory diseases, Implement patient education and communication tactics in collaboration with other members of the healthcare team to improve patient adherence to medication regimens, self-management, and quality of life.

Go online to PeerView.com/DRD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in atopic diseases discusses the relationship between type 2 inflammation and atopic diseases, as well as therapeutic options and strategies to improve patient quality of life. Upon completion of this activity, participants will be able to: Describe the relationship between type 2 inflammation and atopic diseases including asthma, atopic dermatitis, chronic rhinosinusitis with nasal polyps (CRS/NP), and eosinophilic esophagitis (EoE), as well as its relevance to novel biologic therapies, Assess the severity of allergic and inflammatory diseases according to evidence-based guidelines and impact on patient quality of life, Employ the latest clinical evidence with regard to efficacy and safety of novel and emerging biologic therapies to tailor treatment for patients with allergic and inflammatory diseases, Implement patient education and communication tactics in collaboration with other members of the healthcare team to improve patient adherence to medication regimens, self-management, and quality of life.

Go online to PeerView.com/KXJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts discuss strategies to provide optimal care to individual patients with chronic spontaneous urticaria in the context of an advancing treatment landscape. A patient also joins the discussion to provide unique perspectives on living with chronic spontaneous urticaria and interacting with healthcare providers. Upon completion of this activity, participants should be better able to: Recognize physical exam findings and symptomatology suggestive of chronic spontaneous urticaria (CSU), Apply evidence-based diagnostic testing and laboratory evaluation, Employ a guideline-driven approach to the treatment of CSU, Identify patients with refractory disease in whom treatment intensification is warranted, Assess efficacy and safety data related to emerging treatment options for CSU, Recognize the importance of collaboration between specialists and primary care providers to provide optimal treatment and longitudinal support for patients with CSU.

Go online to PeerView.com/KXJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts discuss strategies to provide optimal care to individual patients with chronic spontaneous urticaria in the context of an advancing treatment landscape. A patient also joins the discussion to provide unique perspectives on living with chronic spontaneous urticaria and interacting with healthcare providers. Upon completion of this activity, participants should be better able to: Recognize physical exam findings and symptomatology suggestive of chronic spontaneous urticaria (CSU), Apply evidence-based diagnostic testing and laboratory evaluation, Employ a guideline-driven approach to the treatment of CSU, Identify patients with refractory disease in whom treatment intensification is warranted, Assess efficacy and safety data related to emerging treatment options for CSU, Recognize the importance of collaboration between specialists and primary care providers to provide optimal treatment and longitudinal support for patients with CSU.

Go online to PeerView.com/KXJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts discuss strategies to provide optimal care to individual patients with chronic spontaneous urticaria in the context of an advancing treatment landscape. A patient also joins the discussion to provide unique perspectives on living with chronic spontaneous urticaria and interacting with healthcare providers. Upon completion of this activity, participants should be better able to: Recognize physical exam findings and symptomatology suggestive of chronic spontaneous urticaria (CSU), Apply evidence-based diagnostic testing and laboratory evaluation, Employ a guideline-driven approach to the treatment of CSU, Identify patients with refractory disease in whom treatment intensification is warranted, Assess efficacy and safety data related to emerging treatment options for CSU, Recognize the importance of collaboration between specialists and primary care providers to provide optimal treatment and longitudinal support for patients with CSU.

Go online to PeerView.com/KXJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts discuss strategies to provide optimal care to individual patients with chronic spontaneous urticaria in the context of an advancing treatment landscape. A patient also joins the discussion to provide unique perspectives on living with chronic spontaneous urticaria and interacting with healthcare providers. Upon completion of this activity, participants should be better able to: Recognize physical exam findings and symptomatology suggestive of chronic spontaneous urticaria (CSU), Apply evidence-based diagnostic testing and laboratory evaluation, Employ a guideline-driven approach to the treatment of CSU, Identify patients with refractory disease in whom treatment intensification is warranted, Assess efficacy and safety data related to emerging treatment options for CSU, Recognize the importance of collaboration between specialists and primary care providers to provide optimal treatment and longitudinal support for patients with CSU.

Go online to PeerView.com/KXJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts discuss strategies to provide optimal care to individual patients with chronic spontaneous urticaria in the context of an advancing treatment landscape. A patient also joins the discussion to provide unique perspectives on living with chronic spontaneous urticaria and interacting with healthcare providers. Upon completion of this activity, participants should be better able to: Recognize physical exam findings and symptomatology suggestive of chronic spontaneous urticaria (CSU), Apply evidence-based diagnostic testing and laboratory evaluation, Employ a guideline-driven approach to the treatment of CSU, Identify patients with refractory disease in whom treatment intensification is warranted, Assess efficacy and safety data related to emerging treatment options for CSU, Recognize the importance of collaboration between specialists and primary care providers to provide optimal treatment and longitudinal support for patients with CSU.

Go online to PeerView.com/KXJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts discuss strategies to provide optimal care to individual patients with chronic spontaneous urticaria in the context of an advancing treatment landscape. A patient also joins the discussion to provide unique perspectives on living with chronic spontaneous urticaria and interacting with healthcare providers. Upon completion of this activity, participants should be better able to: Recognize physical exam findings and symptomatology suggestive of chronic spontaneous urticaria (CSU), Apply evidence-based diagnostic testing and laboratory evaluation, Employ a guideline-driven approach to the treatment of CSU, Identify patients with refractory disease in whom treatment intensification is warranted, Assess efficacy and safety data related to emerging treatment options for CSU, Recognize the importance of collaboration between specialists and primary care providers to provide optimal treatment and longitudinal support for patients with CSU.

Go online to PeerView.com/KXJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts discuss strategies to provide optimal care to individual patients with chronic spontaneous urticaria in the context of an advancing treatment landscape. A patient also joins the discussion to provide unique perspectives on living with chronic spontaneous urticaria and interacting with healthcare providers. Upon completion of this activity, participants should be better able to: Recognize physical exam findings and symptomatology suggestive of chronic spontaneous urticaria (CSU), Apply evidence-based diagnostic testing and laboratory evaluation, Employ a guideline-driven approach to the treatment of CSU, Identify patients with refractory disease in whom treatment intensification is warranted, Assess efficacy and safety data related to emerging treatment options for CSU, Recognize the importance of collaboration between specialists and primary care providers to provide optimal treatment and longitudinal support for patients with CSU.

Go online to PeerView.com/KXJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts discuss strategies to provide optimal care to individual patients with chronic spontaneous urticaria in the context of an advancing treatment landscape. A patient also joins the discussion to provide unique perspectives on living with chronic spontaneous urticaria and interacting with healthcare providers. Upon completion of this activity, participants should be better able to: Recognize physical exam findings and symptomatology suggestive of chronic spontaneous urticaria (CSU), Apply evidence-based diagnostic testing and laboratory evaluation, Employ a guideline-driven approach to the treatment of CSU, Identify patients with refractory disease in whom treatment intensification is warranted, Assess efficacy and safety data related to emerging treatment options for CSU, Recognize the importance of collaboration between specialists and primary care providers to provide optimal treatment and longitudinal support for patients with CSU.

Go online to PeerView.com/WGM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert discusses strategies to optimize the care of patients with chronic spontaneous urticaria in the primary care setting. Upon completion of this activity, participants should be better able to: Recognize the clinical presentation of chronic spontaneous urticaria and its impact on patient quality of life, Employ evidence-based guidelines to accurately diagnose patients with chronic spontaneous urticaria, Apply therapeutic options for treating chronic spontaneous urticaria in the context of available evidence and current treatment algorithms, Assess key data sets on the efficacy and safety of emerging pharmacologic treatments for chronic spontaneous urticaria

Go online to PeerView.com/WGM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert discusses strategies to optimize the care of patients with chronic spontaneous urticaria in the primary care setting. Upon completion of this activity, participants should be better able to: Recognize the clinical presentation of chronic spontaneous urticaria and its impact on patient quality of life, Employ evidence-based guidelines to accurately diagnose patients with chronic spontaneous urticaria, Apply therapeutic options for treating chronic spontaneous urticaria in the context of available evidence and current treatment algorithms, Assess key data sets on the efficacy and safety of emerging pharmacologic treatments for chronic spontaneous urticaria

Go online to PeerView.com/WGM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert discusses strategies to optimize the care of patients with chronic spontaneous urticaria in the primary care setting. Upon completion of this activity, participants should be better able to: Recognize the clinical presentation of chronic spontaneous urticaria and its impact on patient quality of life, Employ evidence-based guidelines to accurately diagnose patients with chronic spontaneous urticaria, Apply therapeutic options for treating chronic spontaneous urticaria in the context of available evidence and current treatment algorithms, Assess key data sets on the efficacy and safety of emerging pharmacologic treatments for chronic spontaneous urticaria

Go online to PeerView.com/WGM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert discusses strategies to optimize the care of patients with chronic spontaneous urticaria in the primary care setting. Upon completion of this activity, participants should be better able to: Recognize the clinical presentation of chronic spontaneous urticaria and its impact on patient quality of life, Employ evidence-based guidelines to accurately diagnose patients with chronic spontaneous urticaria, Apply therapeutic options for treating chronic spontaneous urticaria in the context of available evidence and current treatment algorithms, Assess key data sets on the efficacy and safety of emerging pharmacologic treatments for chronic spontaneous urticaria

Go online to PeerView.com/WGM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert discusses strategies to optimize the care of patients with chronic spontaneous urticaria in the primary care setting. Upon completion of this activity, participants should be better able to: Recognize the clinical presentation of chronic spontaneous urticaria and its impact on patient quality of life, Employ evidence-based guidelines to accurately diagnose patients with chronic spontaneous urticaria, Apply therapeutic options for treating chronic spontaneous urticaria in the context of available evidence and current treatment algorithms, Assess key data sets on the efficacy and safety of emerging pharmacologic treatments for chronic spontaneous urticaria

Go online to PeerView.com/WGM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert discusses strategies to optimize the care of patients with chronic spontaneous urticaria in the primary care setting. Upon completion of this activity, participants should be better able to: Recognize the clinical presentation of chronic spontaneous urticaria and its impact on patient quality of life, Employ evidence-based guidelines to accurately diagnose patients with chronic spontaneous urticaria, Apply therapeutic options for treating chronic spontaneous urticaria in the context of available evidence and current treatment algorithms, Assess key data sets on the efficacy and safety of emerging pharmacologic treatments for chronic spontaneous urticaria

Go online to PeerView.com/WGM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert discusses strategies to optimize the care of patients with chronic spontaneous urticaria in the primary care setting. Upon completion of this activity, participants should be better able to: Recognize the clinical presentation of chronic spontaneous urticaria and its impact on patient quality of life, Employ evidence-based guidelines to accurately diagnose patients with chronic spontaneous urticaria, Apply therapeutic options for treating chronic spontaneous urticaria in the context of available evidence and current treatment algorithms, Assess key data sets on the efficacy and safety of emerging pharmacologic treatments for chronic spontaneous urticaria

Go online to PeerView.com/WGM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert discusses strategies to optimize the care of patients with chronic spontaneous urticaria in the primary care setting. Upon completion of this activity, participants should be better able to: Recognize the clinical presentation of chronic spontaneous urticaria and its impact on patient quality of life, Employ evidence-based guidelines to accurately diagnose patients with chronic spontaneous urticaria, Apply therapeutic options for treating chronic spontaneous urticaria in the context of available evidence and current treatment algorithms, Assess key data sets on the efficacy and safety of emerging pharmacologic treatments for chronic spontaneous urticaria

*PLEASE READ BEFORE WATCHING* We apologize for the poor audio quality. We've had some hiccups with the microphone we use and are currently working to find a solution. Thank you for your patience! And thanks for watching! -------------------------- In this Grand Rounds, Dr. Jonathan Bernstein discusses chronic cough by first describing the evaluation and differential diagnosis of a patient presenting with chronic cough. He then determines the pathogenesis of chronic cough and defines the approach to diagnosis and treatment of chronic cough.   Some items in this lecture may have come from the lecturer’s personal academic files or have been cited in-line or at the end of the lecture. For more information, see our citation page. Disclaimers©2016 LouisvilleLectures.org